Topic summary

Why oral semaglutide needs an absorption enhancer at all

Compounds › Oral incretins randomised trial orforglipron oral semaglutide SOUL trial Solved

This is a generated summary. It shows the 9 most-liked posts from a topic of 66, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

m.strand_rphTL3Pharmacist Solution2 May 2025#4

Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.

7 likes 15mo

f.amankwahTL2 Moderator20 May 2025#7

Dose numbers for oral formulations are not comparable to injectable ones. The 14 mg oral dose is not equivalent to any injectable dose in the traditional comparison sense. They are different formulations with different pharmacokinetics and cannot be put on the same scale.

24 likes 14mo

q.zhao_qaTL3Quality assurance5 Jun 2025#10

t.wojcik, post #6: post #5 is right about the mechanism and I think understates the practical bit. Orforglipron is a small molecule, not a peptide. That changes almost everything: no absorption enhancer required, no fasting window, chemical synthesis instead of peptide synthesis, different analytical methods entirely. Data from peptide agonists does not… Go to post

Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that changes gastric pH or transit time changes absorption. Food does both.

25 likes in reply to #6 14mo

k.brandl_deTL3Translator · DE20 Jun 2025#13

This follows post #10 rather than contradicting it.

PIONEER programme is phase 3 for oral semaglutide. The trials cover multiple indications and durations. Reading them requires attention to which trial is which because they are not all the same question.

31 likes 13mo

ambient_draftTL3Regular31 Jul 2025#22

post #21 answers the question as asked. The question underneath it is different.

31 likes 12mo

i.aranda_esTL2Translator · ES17 Sep 2025#34

hana.sato, post #2: Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable bioavailability is a chemistry problem, not a dose problem. Go to post

On post #30 — agreed on the reasoning, with one qualification.

Fasting instructions are not optional advice. Taking the tablet with food or with more than a sip of water measurably reduces absorption. This is the one compound in the class where the instructions genuinely determine the exposure.

33 likes in reply to #2 10mo

p.novotnyTL2Regular17 Oct 2025#42

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

28 likes 9mo

n.hartmannTL2 Moderator12 Nov 2025#49

I read post #47 twice before replying, because I had assumed the opposite.

29 likes 8mo

v.bruunTL2 Moderator13 Dec 2025#58

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

30 likes 7mo

Read the full topic (66 posts)

This topic was referenced in

Oral versus injectable exposure: comparing apples to a different fruitCompounds › Oral incretins · 23 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes Compounds › Oral incretins randomised trial SOUL trial oral semaglutide orforglipron Solved The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do not…	+100	104	4.2k	5mo
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold? Compounds › Oral incretins orforglipron SOUL trial oral semaglutide PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session…	+23	27	4.8k	22mo
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Compounds › Oral incretins PIONEER programme SOUL trial randomised trial orforglipron Solved PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please…	+25	29	22k	1d
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Compounds › Oral incretins randomised trial oral semaglutide SOUL trial PIONEER programme Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022)…	+27	31	17k	25d
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Compounds › Oral incretins PIONEER programme orforglipron randomised trial SOUL trial Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021)…		2	17k	6h

Related topics — sharing the tags randomised trial, orforglipron, oral semaglutide

Topic	Participants	Replies	Views	Activity
Hepatic effects of glucagon receptor agonism: the mechanistic worry Compounds › Retatrutide TRIUMPH programme effect size preprint randomised trial Solved Posting this under the heading it deserves: Hepatic effects of glucagon receptor agonism: the mechanistic worry Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read…	+51	56	700	22mo
Oral semaglutide bioavailability and its variability between people — a second dataset Compounds › Oral incretins randomised trial PIONEER programme SOUL trial Closed Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…	+141	154	47k	19mo
Composite endpoints and the component doing the work Evidence › Trials randomised trial surrogate endpoints open label discontinuation & dropout Solved Under review Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I do…	+3	7	33k	13h
Second pass at: Retatrutide dose escalation in the published trials Compounds › Retatrutide retatrutide randomised trial preprint Under review Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim…	+115	125	30k	2y
Open-label extensions: what survives and what does not Evidence › Trials discontinuation & dropout randomised trial estimand Closed Posting this under the heading it deserves: Open-label extensions: what survives and what does not Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with PIONEER 6 ( N Engl J Med ,…		4	22k	3mo